RESEARCH USE ONLY — PROFESSIONAL LABORATORY USE.
This article is for qualified laboratory personnel carrying out in-vitro assays or institutionally approved laboratory animal studies. It is not a home-use, personal-use, human-use, or veterinary-use guide.
The information below must not be used as an administration, formulation, or dosing plan.

Eloralintide, also known as LY3841136, is a complex modified 37-residue amylin analog. The NIH NCATS substance record lists UNII 73G3354J8W, CAS 2883634-40-8, and documents the defining structural modifications: an N-terminal γ-glutamylcysteine, a Cys2–Cys7 methylene thioacetal bridge (djenkolic acid linker), Orn at position 11, α-methyl-Phe at position 15, N2-methyl-Asn at position 22, a Lys26-linked lipid side chain, and a C-terminal tyrosinamide.
KEGG (D12886) lists the intact molecular formula as C201H319N49O65S2, an average molecular weight of 4,526.11 Da, and a monoisotopic exact mass of 4,523.2604 Da. These values describe the intact modified peptide including the Lys26-linked lipid moiety and excluding variable counterions and solvate water; the peptide backbone alone has a substantially lower mass.
The average MW (4,526.11 Da) is used for molarity calculations, while the monoisotopic exact mass (4,523.26 Da) is the value relevant for high-resolution mass spectrometry identity confirmation.[1][2]
Published laboratory studies examined its structure, receptor activity, and effects in rats and monkeys. This article intentionally focuses on molecular, receptor, and nonclinical laboratory data and is not intended to provide a comprehensive review of the clinical development program.
The principal molecular and nonclinical publication was industry-funded, and the authors reported employment and/or equity interests in the sponsor; independent replication should therefore be considered when interpreting the findings. In engineered cells expressing human receptor constructs, eloralintide showed a functional preference for AMY1R over AMY3R and CTR in the reported cAMP assays.
AMY2R was not evaluated in the same complete dataset, so selectivity across the full amylin receptor family has not been fully characterized.[3]
Molecular identity and structure
| Property | Verified information |
|---|---|
| Research code | LY3841136 / LY-3841136 |
| CAS number | 2883634-40-8 |
| UNII | 73G3354J8W |
| Molecular formula (intact) | C201H319N49O65S2 |
| Average molecular weight | 4,526.11 Da (monoisotopic exact mass: 4,523.2604 Da, per KEGG) |
| Main-chain length | 37 residues |
| C-terminus | Amidated (tyrosinamide) |
| Bridge | Methylene thioacetal bridge between Cys2 and Cys7 (djenkolic acid-type linker; not a conventional disulfide) |
| Lipid side chain | A saturated linear C20 diacid attached at Lys26 through two γ-Glu residues |
| Non-standard amino acid substitutions | Orn at position 11, α-methyl-Phe at position 15, N2-methyl-Asn at position 22 |
| Additional structural features | N-terminal γ-glutamylcysteine (γ-Glu¹–Cys²); γ-Glu denotes a γ-glutamyl residue and should not be interpreted as pyroglutamate (pGlu) |
The 37-residue main chain, C-terminal amide, Cys2–Cys7 methylene thioacetal bridge, Lys26 lipid side chain, and modified residues are described in the main structural study. The NCATS record independently confirms the djenkolic acid bridge (UNII 3QHC9R0YFZ), Orn11 (UNII E524N2IXA3), N2-methyl-Asn22 (UNII 4P7WV6A9DT), α-methyl-Phe15 (UNII W4V7K5BM5T), and N-terminal γ-glutamylcysteine (UNII M984VJS48P) as defining structural modifications.[1][3]
Sequence and modified residues
γ-Glu1–Cys2–Asn3–Thr4–Ala5–Thr6–Cys7–Ala8–Thr9–Gly10–Orn11–Leu12–Ala13–Glu14–(α-methyl-Phe)15–Leu16–Val17–Arg18–Ser19–Ser20–Asn21–(N2-methyl-Asn)22–Phe23–Gly24–Pro25–Lys26(C20 diacid–γ-Glu2)–Leu27–Pro28–Pro29–Thr30–Glu31–Val32–Gly33–Ser34–Asn35–Thr36–Tyr37–NH2
Here, γ-Glu denotes a γ-glutamyl residue and should not be interpreted as pyroglutamate (pGlu) unless specifically demonstrated by structural nomenclature. The structural features can be grouped into two categories: non-standard amino acid substitutions (Orn11, α-methyl-Phe15, N2-methyl-Asn22) and other structural modifications (N-terminal γ-Glu, Cys2–Cys7 methylene thioacetal bridge, Lys26 lipid side chain, C-terminal amide).[1][3]
A fixed molecular weight should not be assigned to a TFA, acetate, sodium, or other salt form unless the amount of that counterion is confirmed for the specific batch. Water and retained solvent can also change the measured vial mass, so these values should come from the batch COA.
Amylin receptors
Amylin receptors are formed from the calcitonin receptor (CTR) together with a receptor activity-modifying protein (RAMP). CTR with RAMP1 forms AMY1R, CTR with RAMP2 forms AMY2R, and CTR with RAMP3 forms AMY3R.[4]
The main eloralintide study compared human and rat AMY1R, AMY3R, and CTR constructs. It did not report the same full set of cAMP and binding results for AMY2R, so selectivity across the complete amylin receptor family has not been fully characterized.
The article should not claim that eloralintide is inactive at AMY2R, nor should the term “selective” be used without specifying which receptors were compared.
Receptor activity in cell assays
The study used UMUC3 cells engineered to express human or rat receptor constructs. It measured cAMP production and competitive ligand binding.
Lower EC50 values indicate greater functional potency, whereas lower Ki values indicate higher binding affinity within the specified assay system. Neither value alone establishes greater efficacy (maximum response), which should be evaluated using parameters such as Emax.[3]
| Receptor construct | cAMP EC50 | Binding Ki |
|---|---|---|
| Human AMY1R | 23.9 pM | 478.1 pM |
| Human AMY3R | 253.8 pM | 3,608.9 pM |
| Human CTR | 291.0 pM | 3,896.1 pM |
| Rat AMY1R | 5.4 pM | 48.1 pM |
| Rat AMY3R | 13.8 pM | 161.0 pM |
| Rat CTR | 243.2 pM | 5,263.3 pM |
In the human receptor assays, eloralintide showed approximately 11-fold greater functional potency at AMY1R than at AMY3R and approximately 12-fold greater potency at AMY1R than at CTR. In the rat assays, it was potent at both AMY1R and AMY3R (only ~2.6-fold difference), with much weaker potency at CTR.
The human AMY1R vs AMY3R preference is substantially larger than the rat AMY1R vs AMY3R preference, and results from the two species should not be averaged or combined.[3]
These numbers apply only to the reported assay. Cell type, receptor expression level, albumin in the medium, incubation time, and the method used can all change the apparent potency.
Human and rat results should therefore be shown separately and should not be combined into one cross-species ranking.
Findings from laboratory animal studies
The results below summarize published laboratory studies. They are not an administration or dosing guide.
Pharmacokinetics in rats and monkeys
In dose-matched pharmacokinetic comparisons within each species, conducted using the study-specific formulations reported by the investigators (the two peptides used different formulation conditions, including different pH values), eloralintide showed higher exposure, a longer apparent half-life, and a flatter concentration-time profile than cagrilintide. The comparison doses were approximately 30 nmol/kg in male Sprague-Dawley rats and approximately 20 nmol/kg in cynomolgus monkeys.
These results apply to the exact species, formulations, and study methods used by the researchers.[3]
Food intake and body weight in lean rats
At the 96-hour endpoint following a single administration in male lean Sprague-Dawley rats, the food-intake ED50 was 3.7 nmol/kg for eloralintide and 8.5 nmol/kg for cagrilintide. The corresponding body-weight ED50 values were 6.1 and 11.4 nmol/kg, respectively; the difference in the body-weight ED50 comparison was not statistically significant.
These values represent cumulative or endpoint effects over 96 hours following a single dose and should not be treated as steady-state or multi-dose potency estimates.[3]
Body composition in diet-induced obese rats
In a separate repeated-dose study in diet-induced obese Long-Evans rats, using a once-every-three-days study schedule and quantitative NMR body-composition assessment, the day-13 fat-mass ED50 was reported as 0.8 nmol/kg for eloralintide and 2.7 nmol/kg for cagrilintide. Substantially more of the body-weight change came from fat-mass reduction than from lean-mass change.
This study design differs from the single-dose lean-rat experiment in species, dosing schedule, duration, and endpoint, and the ED50 values from the two studies should not be treated as directly comparable or rank-ordered across studies.[3]
Conditioned taste avoidance
Eloralintide caused less conditioned taste avoidance than cagrilintide in the reported lean-rat study. This test measures learned avoidance behavior in rodents.
It is not the same as directly measuring nausea or general gastrointestinal safety, and it does not by itself prove which receptor caused the difference.[3]
COA and laboratory handling
A COA describes one batch. It should not be treated as proof that the material is suitable for every experiment.
For a complex modified peptide such as eloralintide—containing a 37-residue main chain, multiple non-standard amino acids, a methylene thioacetal bridge, site-specific Lys26 lipidation through two γ-Glu residues, a C20 diacid, and a C-terminal amide—intact-mass MS and a single RP-HPLC purity result are not sufficient for complete structural and quality confirmation. Orthogonal analytical methods are needed to independently verify sequence, modification-site specificity, bridge chemistry, and impurity profiles.[3]
| COA item | What it means |
|---|---|
| Intact-mass LC-MS | Confirms the overall molecular mass. Does not by itself verify sequence order, modification sites, bridge chemistry, or the absence of isobaric impurities. |
| Peptide mapping or LC-MS/MS | Confirms amino-acid sequence, identifies modification sites (e.g., correct Lys26 lipidation versus mis-acylation at other positions), and detects sequence-related impurities such as deletions, truncations, and insertions. |
| Orthogonal chromatography | Reduces the risk of co-eluting impurities being missed by a single RP-HPLC method. Different separation mechanisms can reveal impurities not resolved by one column chemistry. |
| HPLC or UPLC purity | Shows chromatographic area purity under the stated method. It is not automatically the same as peptide content by weight, and a single-area purity result does not independently confirm bridge chemistry or modification-site specificity. |
| Bridge chemistry confirmation | Verifies that the Cys2–Cys7 bridge is the expected methylene thioacetal (not a mis-formed disulfide, free thiols, or other cross-linked species). May require reduced/non-reduced comparisons, chemical stability data, or targeted MS analysis. |
| Site-specific lipidation | Verifies that the C20 diacid–γ-Glu2 modification is attached at Lys26 and not at other lysine or reactive residues. Free unconjugated peptide and free lipid-linker species should also be assessed. |
| Peptide content (assay) | Quantifies the actual peptide in the weighed material, accounting for water, counterions, and other components. HPLC area purity alone is not a substitute. |
| Chiral / stereochemical purity | Checks for epimerization or incorrect stereochemistry at modified residues (Orn11, α-methyl-Phe15, N2-methyl-Asn22), which may not be distinguishable by achiral RP-HPLC. |
| Counterions and residuals | TFA, acetate, sodium, water, and residual solvents should be reported separately when relevant. |
| Aggregates and higher-molecular-weight species | Detects dimers, oligomers, and aggregates that may form during storage or reconstitution. These species may not be adequately resolved by a standard purity HPLC method. |
| Endotoxin or bioburden | Must be checked against the needs of the planned laboratory assay. “Research grade” does not automatically mean sterile or low endotoxin. |
Analytical procedure validation characteristics should be selected according to the intended purpose of the method. Identity procedures generally emphasize specificity, whereas quantitative assay and impurity procedures typically require appropriate evaluation of specificity, response and range, accuracy, and precision.
Limit tests follow a different validation scheme. Not every method is expected to demonstrate every validation characteristic uniformly.
ICH Q2(R2) describes these principles for regulated pharmaceutical analytical procedures and is cited here for general quality-awareness purposes; it does not directly establish a mandatory specification for a research-use-only material.[5]
This article does not give a universal solvent, reconstitution recipe, or solution shelf life. Those details can change with salt form, purity, concentration, buffer, container, and temperature.
Follow the batch COA and validated laboratory data, test a small amount first, and confirm physical dissolution. Verify solution concentration, integrity, and stability using an appropriate validated or qualified analytical method—visual clarity alone does not establish chemical stability, recovery, or the absence of soluble aggregates.
Main limits of the published data
- The receptor numbers come from engineered cell assays and can change in another assay system.
- Human and rat receptor results are different and should not be mixed. The human AMY1R vs AMY3R preference (~11-fold) is substantially larger than the rat preference (~2.6-fold).
- The main receptor comparison does not provide a complete AMY2R data set. The term “selective” should not be applied without specifying which receptors were compared.
- Results from rats and monkeys do not provide a human or veterinary use plan. ED50 values are specific to the species, study design, dosing schedule, and time point; ED50 values from different study designs (single-dose 96-hour endpoint vs. repeated-dose day-13 NMR) should not be treated as directly comparable.
- Storage and solution stability must be checked for the specific batch and formulation using validated analytical methods.
- The principal publication was industry-funded. Independent replication should be considered when interpreting the findings.
Research sources
- NIH National Center for Advancing Translational Sciences. Inxight Drugs: Eloralintide, UNII 73G3354J8W. Documents defining structural modifications: djenkolic acid bridge (Cys2-Cys7), Orn11, N2-methyl-Asn22, α-methyl-Phe15, N-terminal γ-Glu-Cys, Lys26 lipid, C-terminal tyrosinamide. https://drugs.ncats.io/substance/73G3354J8W
- KEGG DRUG. D12886: Eloralintide. Molecular formula C201H319N49O65S2, average MW 4,526.11 Da, exact mass 4,523.2604 Da. https://www.kegg.jp/entry/D12886
- Briere DA, et al. Eloralintide, a long-acting amylin receptor agonist, elicits body weight loss through amylin-based pharmacology, without reducing lean mass. Molecular Metabolism. 2025;102:102271. PMID: 41109426. DOI: 10.1016/j.molmet.2025.102271. Industry-funded; authors reported employment/equity interests in the sponsor. https://pmc.ncbi.nlm.nih.gov/articles/PMC12640043/
- Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. British Journal of Pharmacology. 2018;175(1):3-17. https://pmc.ncbi.nlm.nih.gov/articles/PMC5740251/
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. Validation characteristics should be selected according to the intended purpose of the method; identity/assay/impurity/limit tests require different validation schemes. https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130.pdf
Research Use Only Disclaimer
Research Use Only: The eloralintide material described on this page is supplied for laboratory research purposes only and is not intended for human or veterinary use. This article provides an informational summary of published molecular, receptor, and nonclinical laboratory data and general analytical-quality considerations.
It does not provide a validated experimental protocol, medical advice, veterinary advice, dosing instructions, or authorization for in vivo work. Any animal research must be conducted under applicable institutional approvals and legal requirements.
For a side-by-side look at structure, receptor selectivity and how to tell the two amylin analogs apart analytically, see our guide to eloralintide vs cagrilintide. For a different-mechanism research comparison of AMY1R-preferring eloralintide versus the triple-agonist scaffold retatrutide (not a head-to-head trial), see eloralintide vs retatrutide. Research-grade reference material for laboratory assay work is listed on the Eloralintide peptide (LY3841136) product page.